A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD)
Influenza, Human
Phase 3
An analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013